FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
pharmaphorum1d
Advantage BMS as AbbVie drug fails schizophrenia trials
Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. Discover how AI is ...
Hosted on MSN13d
FDA approves new drug for schizophrenia, promises few side effects
A new drug could be a breakthrough in treating schizophrenia. Here's how it's different from current treatments.
MedCity News4d
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test
Weeks after that announcement, BMS announced a $14 billion deal to buy Karuna Therapeutics, whose M1- and M4-targeting schizophrenia drug was already under FDA review. The September approval of ...
Morningstar4d
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a ...
The Hindu23d
FDA approval for Cobenfy casts light on schizophrenia’s wickedness
On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...
Seeking Alpha4d
AbbVie declines after missing main goal in schizophrenia treatment trials
Bristol Myers Squibb (BMY), which received FDA approval for its schizophrenia drug in September, gained 13%.
Seeking Alpha13d
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults with schizophrenia. Citing new topline data from its 52-week open-label studies ...